:PRS-220 针对的是肺纤维化关键靶点 CCN2。在特发性肺纤维化(IPF)患者的肺组织中,CCN2 蛋白水平升高,驱动肺组织纤维化进程。PRS-220 通过特异性结合 CCN2,阻断相关信号通路,减少细胞外基质生成和肌成纤维细胞活化,从而抑制肺纤维...
凤凰网港股|Pieris制药公司(PIRS)宣布开发PRS-220,一种针对结缔组织生长因子(CTGF)(CCN2的口服吸入性抗癌蛋白),用于治疗特发性肺纤维化(IPF)。 该公司还宣布它已被选中获得巴伐利亚州经济事务、地区发展和能源部提供的1700万美元的资助,用于研究和开发PRS-220治疗SARS-CoV-2感染的急性后遗症,或PASC,肺纤维化,或...
PRS-220 is an inhalable Anticalin protein targeting CTGF in development as a novel therapy for fibrotic lung disease including IPF.Objective: We investigate the nebulization performance and in vivo lung biodistribution of PRS-220 to characterize its profile for inhaled lung delivery.Methods: The ...
PRS-220 is an inhaled Anticalin protein targeting CTGF for the treatment of IPF and other fibrotic lung diseases. Previously reported preclinical data for PRS-220 demonstrated superior on-target potency compared to pamrevlumab, an intravenously infused CTGF antagonist in late-stage clinica...
First clinical validation of this target in IPF has been provided by positive results of a systemically-delivered antibody in Phase 2 clinical studies. Anticalin proteins derived from human lipocalins can be engineered to bind to their targets with high potency and selectivity, similar to antibodies...